Skip to content

Study · Case report or series · n = 1 · 2026

6 results

Off-label palopegteriparatide for severe pediatric postsurgical hypocalcemia.

Pérez Reyes P, Rebollo Román Á, Alhambra Expósito MR, Padillo Cuenca JC, Serrano Laguna MDC, Moreno Moreno P, Rodríguez Camacho JM, Gálvez Moreno MÁ

European journal of endocrinology1 Oct 2026

PMID42789535 (opens in a new tab)DOI10.1093/ejendo/lvag186 (opens in a new tab)PepBankPUB-42789535
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a boy with postsurgical hypocalcemia, serum calcium improved within 48 h after palopegteriparatide initiation.

    In plain wordsIn a boy with postsurgical hypocalcemia, serum calcium improved within 48 h after palopegteriparatide initiation.

    Peptide
    Palopegteriparatide
    Outcome
    IncreaseSerum calcium improvement
    Study

    n = 1

    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Time to serum calcium improvement
    ≤ 48 h
    after palopegteriparatide start

    Source sentences

    Summary
    Serum calcium improved within 48 h, intravenous calcium was stopped after 5 days, and calcitriol, sevelamer, and calcium acetate were discontinued within 11 days.
    2 context sentences
    Summary · context
    We report the case of a 14-year-old boy with Graves' disease who developed profound postoperative hypocalcemia after total thyroidectomy, with serum calcium 5.9 mg/dL, ionized calcium 0.83 mmol/L, and undetectable parathyroid hormone.
    Summary · context
    Off-label subcutaneous palopegteriparatide, a long-acting PTH(1-34) prodrug, was started after multidisciplinary assessment and informed consent from the family.
  2. 02HumanCase report or seriesEfficacy outcome

    In a boy with postsurgical hypocalcemia, intravenous calcium stopped after 5 days following palopegteriparatide initiation.

    In plain wordsIn a boy with postsurgical hypocalcemia, intravenous calcium stopped after 5 days following palopegteriparatide initiation.

    Peptide
    Palopegteriparatide
    Outcome
    DecreaseIntravenous calcium discontinuation
    Study

    n = 1

    Outcome group
    Conventional therapy requirements · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Time to intravenous calcium discontinuation
    5 days
    after palopegteriparatide start

    Source sentences

    Summary
    Serum calcium improved within 48 h, intravenous calcium was stopped after 5 days, and calcitriol, sevelamer, and calcium acetate were discontinued within 11 days.
    2 context sentences
    Summary · context
    We report the case of a 14-year-old boy with Graves' disease who developed profound postoperative hypocalcemia after total thyroidectomy, with serum calcium 5.9 mg/dL, ionized calcium 0.83 mmol/L, and undetectable parathyroid hormone.
    Summary · context
    Off-label subcutaneous palopegteriparatide, a long-acting PTH(1-34) prodrug, was started after multidisciplinary assessment and informed consent from the family.
  3. 03HumanCase report or seriesEfficacy outcome

    In a boy with postsurgical hypocalcemia, calcitriol stopped within 11 days following palopegteriparatide initiation.

    In plain wordsIn a boy with postsurgical hypocalcemia, calcitriol stopped within 11 days following palopegteriparatide initiation.

    Peptide
    Palopegteriparatide
    Outcome
    DecreaseCalcitriol discontinuation
    Study

    n = 1

    Outcome group
    Conventional therapy requirements · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Time to calcitriol discontinuation
    ≤ 11 days
    after palopegteriparatide start

    Source sentences

    Summary
    Serum calcium improved within 48 h, intravenous calcium was stopped after 5 days, and calcitriol, sevelamer, and calcium acetate were discontinued within 11 days.
    2 context sentences
    Summary · context
    We report the case of a 14-year-old boy with Graves' disease who developed profound postoperative hypocalcemia after total thyroidectomy, with serum calcium 5.9 mg/dL, ionized calcium 0.83 mmol/L, and undetectable parathyroid hormone.
    Summary · context
    Off-label subcutaneous palopegteriparatide, a long-acting PTH(1-34) prodrug, was started after multidisciplinary assessment and informed consent from the family.
  4. 04HumanCase report or seriesEfficacy outcome

    In a boy with postsurgical hypocalcemia, sevelamer stopped within 11 days following palopegteriparatide initiation.

    In plain wordsIn a boy with postsurgical hypocalcemia, sevelamer stopped within 11 days following palopegteriparatide initiation.

    Peptide
    Palopegteriparatide
    Outcome
    DecreaseSevelamer discontinuation
    Study

    n = 1

    Outcome group
    Conventional therapy requirements · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Time to sevelamer discontinuation
    ≤ 11 days
    after palopegteriparatide start

    Source sentences

    Summary
    Serum calcium improved within 48 h, intravenous calcium was stopped after 5 days, and calcitriol, sevelamer, and calcium acetate were discontinued within 11 days.
    2 context sentences
    Summary · context
    We report the case of a 14-year-old boy with Graves' disease who developed profound postoperative hypocalcemia after total thyroidectomy, with serum calcium 5.9 mg/dL, ionized calcium 0.83 mmol/L, and undetectable parathyroid hormone.
    Summary · context
    Off-label subcutaneous palopegteriparatide, a long-acting PTH(1-34) prodrug, was started after multidisciplinary assessment and informed consent from the family.
  5. 05HumanCase report or seriesEfficacy outcome

    In a boy with postsurgical hypocalcemia, calcium acetate stopped within 11 days following palopegteriparatide initiation.

    In plain wordsIn a boy with postsurgical hypocalcemia, calcium acetate stopped within 11 days following palopegteriparatide initiation.

    Peptide
    Palopegteriparatide
    Outcome
    DecreaseCalcium acetate discontinuation
    Study

    n = 1

    Outcome group
    Conventional therapy requirements · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Time to calcium acetate discontinuation
    ≤ 11 days
    after palopegteriparatide start

    Source sentences

    Summary
    Serum calcium improved within 48 h, intravenous calcium was stopped after 5 days, and calcitriol, sevelamer, and calcium acetate were discontinued within 11 days.
    2 context sentences
    Summary · context
    We report the case of a 14-year-old boy with Graves' disease who developed profound postoperative hypocalcemia after total thyroidectomy, with serum calcium 5.9 mg/dL, ionized calcium 0.83 mmol/L, and undetectable parathyroid hormone.
    Summary · context
    Off-label subcutaneous palopegteriparatide, a long-acting PTH(1-34) prodrug, was started after multidisciplinary assessment and informed consent from the family.
  6. 06HumanCase report or seriesSafety outcome

    In a boy with postsurgical hypocalcemia, palopegteriparatide was well tolerated.

    In plain wordsIn a boy with postsurgical hypocalcemia, palopegteriparatide was well tolerated.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableTolerability
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Treatment was well tolerated.
    2 context sentences
    Summary · context
    We report the case of a 14-year-old boy with Graves' disease who developed profound postoperative hypocalcemia after total thyroidectomy, with serum calcium 5.9 mg/dL, ionized calcium 0.83 mmol/L, and undetectable parathyroid hormone.
    Summary · context
    Off-label subcutaneous palopegteriparatide, a long-acting PTH(1-34) prodrug, was started after multidisciplinary assessment and informed consent from the family.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.